<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888718</url>
  </required_header>
  <id_info>
    <org_study_id>671/10</org_study_id>
    <nct_id>NCT01888718</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of Allegra ® (Containing Fexofenadine Hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi - Aventis U.S. LLC, Bridgewater, NJ 08807 in Healthy, Adult, Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the bioequivalence of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30
      mg of Dr. Reddy's Laboratories Limited, India comparing with that of Allegra® (containing
      fexofenadine hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi - aventis U.S. LLC,
      Bridgewater, NJ 08807 in healthy, adult, human subjects under fasting conditions. To monitor
      adverse events and ensure the safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose,
      Crossover, Oral Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrating
      Tablets 30 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of Allegra ®
      (Containing Fexofenadine Hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi -
      Aventis U.S. LLC, Bridgewater, NJ 08807 in Healthy, Adult, Human Subjects Under Fasting
      Conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose (0.0) and 0.167, 0.33, 0.50, 0.75, 1.25, 1.5, 1.75, 2, 2.33, 2.67, 3, 3.50, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fexofenadine Hydrochloride Orally Disintegrating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr.Reddy's Laboratories Ltd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALLEGRA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALLEGRA orally disintegrating tablets 30 mg of Sanofi Aventis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine Hydrochloride</intervention_name>
    <description>Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg</description>
    <arm_group_label>Fexofenadine Hydrochloride Orally Disintegrating</arm_group_label>
    <arm_group_label>ALLEGRA</arm_group_label>
    <other_name>ALLEGRA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Provide written informed consent.

        ii. Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive)
        weighing at least 50 kg.

        iii. Having a body mass index between 18.5 and 24.9 (both inclusive), calculated as weight
        in Kg/height in m2.

        iv. Must be of normal health as determined by medical history, physical examination and
        laboratory investigation performed within 28 days prior to the commencement of the study.
        (Laboratory values must be within normal limits or considered by the physician /
        investigator to be of no clinical significance).

        v. Female Subjects

          -  of child bearing potential practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms, foams,
             jellies, diaphragm, intrauterine device (IUD), or abstinence.

          -  surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
             has been performed on the subject)

        Exclusion Criteria

        i.Incapable of understanding the informed consent.

        ii. Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.

        iii. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.

        iv. Oral temperature is below 95.0°F or above 98.6°F.

        v. Pulse rate below 50/min or above 100/min.

        vi. History of hypersensitivity or idiosyncratic reaction to investigational drug product
        or any other related drugs.

        vii. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
        function.

        viii. Consumption of grapefruit for the past ten days prior to the check-in, in each
        period.

        ix. Regular smoker who has a habit of smoking more than nine cigarettes per day and has
        difficulty in abstaining from smoking during sample collection period.

        x. Habit of tobacco chewing.

        xi. Habit of alcoholism and difficulty in abstaining from alcohol during the sample
        collection period.

        xii. Difficulty in abstaining from xanthine containing food or beverages (like tea, coffee,
        chocolates and cola drinks) during the sample collection period.

        xiii. Intake of over the counter (OTC) or prescribed medications and enzyme modifying
        medication or systemic medication for the last 30 days before dosing.

        xiv. Clinically significant abnormalities and / or with significant diseases. xv. Confirmed
        positive in alcohol screening.

        xvi. Confirmed positive in selected drug of abuse.

        xvii. Participated in any other clinical investigation using experimental drug/donated
        blood in past 90 days before the date of start of study.

        xviii. Confirmed positive in urine pregnancy test.

        xix. Female detected to be pregnant, breast feeding or who is likely to become pregnant
        during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Vimal Teja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Private Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Private Limited</name>
      <address>
        <city>Balanagar</city>
        <state>Hyderabad, Andhra Pradesh</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

